Substituted benzothienyl-pyrrolotriazines and uses thereof

1. A compound of formula (I)

wherein

R 1 is hydrogen, chloro, methyl or methoxy,

R 2 is hydrogen or methoxy,

with the proviso that at least one of R 1 and R 2 is other than hydrogen, and

G represents the group —CH 2 —OR 3 , —CH 2 —NR 4 R 5 or —C(═O)—NR 6 R 7 , wherein

R 3 is (C 1 -C 6 )-alkyl substituted with a residue selected from the group consisting of amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, aminocarbonyl, mono-(C 1 -C 4 )-alkylaminocarbonyl, di-(C 1 -C 4 )-alkylaminocarbonyl and 4- to 6-membered heterocycloalkyl, or

is 4- to 6-membered heterocycloalkyl,

wherein said 4- to 6-membered heterocycloalkyl groups are optionally substituted with one or two residues independently selected from the group consisting of (C 1 -C 4 )-alkyl, oxo, hydroxy, amino and aminocarbonyl,

R 4 is hydrogen or (C 1 -C 4 )-alkyl,

R 5 is (C 1 -C 6 )-alkyl substituted with one or two residues independently selected from the group consisting of hydroxy, (C 1 -C 4 )-alkoxy, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, hydroxycarbonyl, aminocarbonyl, mono-(C 1 -C 4 )-alkylamino-carbonyl, di-(C 1 -C 4 )-alkylaminocarbonyl, (C 1 -C 4 )-alkylcarbonylamino, aminocarbonylamino and 4- to 6-membered heterocycloalkyl,

wherein said 4- to 6-membered heterocycloalkyl is optionally substituted with one or two residues independently selected from the group consisting of (C 1 -C 4 )-alkyl, oxo, hydroxy, amino and amino-carbonyl, or

is (C 1 -C 4 )-alkylcarbonyl optionally substituted with a residue selected from the group consisting of hydroxy, (C 1 -C 4 )-alkoxy, amino, mono-(C 1 -C 4 )-alkylamino and di-(C 1 -C 4 )-alkylamino, or

is (C 3 -C 6 )-cycloalkyl optionally substituted with one or two residues independently selected from the group consisting of (C 1 -C 4 )-alkyl, hydroxy, (C 1 -C 4 )-alkoxy, amino, mono-(C 1 -C 4 )-alkylamino and di-(C 1 -C 4 )-alkylamino, or

is 4- to 6-membered heterocycloalkyl optionally substituted with one or two residues independently selected from the group consisting of (C 1 -C 4 )-alkyl, oxo, hydroxy, amino and aminocarbonyl,

or

R 4 and R 5 are joined and, taken together with the nitrogen atom to which they are attached, form a mono- or bicyclic, saturated, 4- to 10-membered heterocycloalkyl ring which may contain a second ring heteroatom selected from N and O, and which may be substituted with up to three residues independently selected from the group consisting of (C 1 -C 4 )-alkyl, oxo, hydroxy, (C 1 -C 4 )-alkoxy, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, azetidino, pyrrolidino, piperidino, (C 1 -C 4 )-alkyl-carbonyl, (C 3 -C 6 )-cycloalkylcarbonyl, hydroxycarbonyl, am inocarbonyl, mono-(C 1 -C 4 )-alkylaminocarbonyl, di-(C 1 -C 4 )-alkylaminocarbonyl, thienyl and phenyl,

wherein the alkyl groups of said (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkoxy, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino and (C 1 -C 4 )-alkyl-carbonyl residues, for their part, are optionally substituted with a residue selected from the group consisting of hydroxy, amino and am inocarbonyl,

and

wherein said thienyl and phenyl groups are optionally substituted with one or two residues independently selected from the group consisting of fluoro, chloro, cyano, methyl and trifluoromethyl,

or

R 4 and R 5 are joined and, taken together with the nitrogen atom to which they are attached, form an imidazol-1-yl or 1,2,4-triazol-1-yl ring each of which may be substituted with one or two residues independently selected from the group consisting of (C 1 -C 4 )-alkyl and cyano,

R 6 is hydrogen,

R 7 is 4- to 6-membered heterocycloalkyl optionally substituted with one or two residues independently selected from the group consisting of (C 1 -C 4 )-alkyl, oxo, hydroxy, amino and aminocarbonyl,

or

R 6 and R 7 are joined and, taken together with the nitrogen atom to which they are attached, form a monocyclic, saturated, 4- to 7-membered heterocycloalkyl ring which may contain a second ring heteroatom selected from N and O, and which may be substituted with one or two residues independently selected from the group consisting of (C 1 -C 4 )-alkyl, oxo, hydroxy, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkyl-amino and aminocarbonyl,

or a pharmaceutically acceptable salt thereof.

2. The compound of formula (I) according to claim 1 , wherein

R 1 is chloro or methyl,

R 2 is methoxy,

and

G represents the group —CH 2 —OR 3 , —CH 2 —NR 4 R 5 or —C(═O)—NR 6 R 7 , wherein

R 3 is (C 2 -C 4 )-alkyl substituted with a residue selected from the group consisting of amino, mono-(C 1 -C 4 )-alkylamino and pyrrolidin-1-yl,

or

is pyrrolidin-3-yl,

R 4 is hydrogen or methyl,

R 5 is (C 1 -C 4 )-alkyl substituted with a residue selected from the group consisting of hydroxy, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkylamino, aminocarbonyl and mono-(C 1 -C 4 )-alkylaminocarbonyl,

or

is (C 1 -C 4 )-alkylcarbonyl optionally substituted with amino,

or

is (C 3 -C 6 )-cycloalkyl optionally substituted with a residue selected from the group consisting of hydroxy, amino, mono-(C 1 -C 4 )-alkyl-amino and di-(C 1 -C 4 )-alkylamino,

or

is 5- or 6-membered heterocycloalkyl optionally substituted with one or two residues independently selected from the group consisting of (C 1 -C 4 )-alkyl, oxo and amino,

or

R 4 and R 5 are joined and, taken together with the nitrogen atom to which they are attached, form a monocyclic, saturated, 4- to 7-membered heterocycloalkyl ring which may contain a second ring heteroatom selected from N and O, and which may be substituted with up to three residues independently selected from the group consisting of (C 1 -C 4 )-alkyl, oxo, hydroxy, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkyl-amino, (C 1 -C 4 )-alkylcarbonyl, (C 3 -C 6 )-cycloalkylcarbonyl, aminocarbonyl and mono-(C 1 -C 4 )-alkylaminocarbonyl,

wherein the alkyl groups of said (C 1 -C 4 )-alkyl, mono-(C 1 -C 4 )-alkyl-amino, di-(C 1 -C 4 )-alkylamino and (C 1 -C 4 )-alkylcarbonyl residues, for their part, are optionally substituted with hydroxy,

R 6 is hydrogen,

R 7 is 5- or 6-membered heterocycloalkyl optionally substituted with one or two residues independently selected from the group consisting of (C 1 -C 4 )-alkyl, oxo and amino,

or

R 6 and R 7 are joined and, taken together with the nitrogen atom to which they are attached, form a monocyclic, saturated, 5- to 7-membered heterocycloalkyl ring which may contain a second ring heteroatom selected from N and O, and which may be substituted with one or two residues independently selected from the group consisting of (C 1 -C 4 )-alkyl, oxo, hydroxy, amino, mono-(C 1 -C 4 )-alkylamino, di-(C 1 -C 4 )-alkyl-amino and aminocarbonyl,

or a pharmaceutically acceptable salt thereof.

3. The compound of formula (I) according to claim 1 , wherein

R 1 is methyl,

R 2 is methoxy,

and

G represents the group —CH 2 —NR 4 R 5 or —C(═O)—NR 6 R 7 , wherein

R 4 is hydrogen,

R 5 is (C 1 -C 4 )-alkyl substituted with amino, methylamino or amino-carbonyl,

or

is (C 1 -C 4 )-alkylcarbonyl substituted with amino,

or

is 2-oxopyrrolidin-3-yl or 2-oxopiperidin-3-yl,

or

R 4 and R 5 are joined and, taken together with the nitrogen atom to which they are attached, form a pyrrolidin-1-yl, piperidin-1-yl or piperazin-1-yl ring each of which may be substituted with one or two residues independently selected from the group consisting of methyl, oxo, hydroxy, amino, methylamino, dimethylamino and aminocarbonyl,

R 6 is hydrogen,

R 7 is 2-oxopyrrolidin-3-yl or 2-oxopiperidin-3-yl,

or

R 6 and R 7 are joined and, taken together with the nitrogen atom to which they are attached, form a pyrrolidin-1-yl, piperidin-1-yl or piperazin-1-yl ring each of which may be substituted with one or two residues independently selected from the group consisting of methyl, oxo, hydroxy, amino, methylamino, dimethylamino and aminocarbonyl,

or a pharmaceutically acceptable salt thereof.

4. A process for preparing a compound of formula (I) according to claim 1 , comprising either

[A] reacting 4-aminopyrrolo[2,1-f][1,2,4]triazine of formula (II)

with formaldehyde and an amine of formula (III)

wherein R 4 and R 5 are defined in claim 1 ,

in the presence of an acid to give a compound of formula (IV)

wherein R 4 and R 5 are defined in claim 1 , brominating the compound of formula (IV) to a compound of formula (V)

wherein R 4 and R 5 are defined in claim 1 , and coupling the compound of formula (V) with a benzothiophen-2-yl boronate of formula (VI)

wherein R 1 and R 2 are defined in claim 1 ,

and

R 8 represents hydrogen or (C 1 -C 4 )-alkyl, or both R 8 residues are linked together to form a —(CH 2 ) 2 —, —C(CH 3 ) 2 —C(CH 3 ) 2 —, —(CH 2 ) 3 —, —CH 2 —C(CH 3 ) 2 —CH 2 —or —C(═O )—CH 2 —N(CH 3 )—CH 2 —C(═O)—bridge,

in the presence of a palladium catalyst and a base to yield the target compound of formula (I-A)

wherein R 1 , R 2 , R 4 and R 5 are defined in claim 1 ,

or

[B] treating 4-aminopyrrolo[2, 1-f][1,2,4]triazine of formula (II)

with N,N-dimethylformamide in the presence of phosphoryl chloride to give a formyl compound of formula (VII)

brominating the compound of formula (VII) to a compound of formula (VIII)

and coupling the compound of formula (VIII) with a benzothiophen-2-yl boronate of formula (VI)

wherein R 1 , R 2 and R 8 are defined in claim 1 ,

in the presence of a palladium catalyst and a base to give a compound of formula (IX)

wherein R 1 and R 2 are defined in claim 1 ,

and either

[B-1] reacting the compound of formula (IX) with an amine of formula (III)

wherein R 4 and R 5 are defined in claim 1 ,

in the presence of an acid and a reducing agent to yield the target compound of formula (I-A)

wherein R 1 , R 2 , R 4 and R 5 are defined in claim 1 ,

or

[B-2] oxidizing the compound of formula (IX) to a carboxylic acid of formula (X)

wherein R 1 and R 2 are defined in claim 1 ,

and coupling the compound of formula (X) with an amine of formula (XI)

wherein R 6 and R 7 are defined in claim 1 ,

in the presence of a condensing agent to yield the target compound of formula (I-B)

wherein R 1 , R 2 , R 6 and R 7 are defined in claim 1 ,

or

[B-3] reducing the compound of formula (IX) to an alcohol of formula (XII)

wherein R 1 and R 2 are defined in claim 1 ,

converting the compound of formula (XII) into the corresponding halomethyl derivative of formula (XIII)

wherein R 1 and R 2 are defined in claim 1 ,

and

X is chloro, bromo or iodo,

and treating the compound of formula (XIII) with an alcohol of formula (XIV)

R 3 —OH  (XIV),

wherein R 3 is defined in claim 1 ,

in the optional presence of a base to yield the target compound of formula (I-C)

wherein R 1 , R 2 and R 3 are defined in claim 1 , optionally followed by (i) separating the compound of formula (I) into its enantiomers and/or diastereomers, or (ii) converting the compound of formula (I) into a salt thereof by treatment with a solvent and/or acid or base.

5. A pharmaceutical composition comprising a compound as defined in claim 1 and one or more pharmaceutically acceptable excipients.

6. The pharmaceutical composition of claim 5 further comprising one or more additional therapeutic agents.